Cargando…
Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
The unexpectedly low vaccine efficacy of Dengvaxia®, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816432/ https://www.ncbi.nlm.nih.gov/pubmed/31314657 http://dx.doi.org/10.1080/21645515.2019.1643676 |